Cargando…
Impact of Time to Castration Resistance on Cytoreductive Radiotherapy in Metastatic Castration-Resistant Prostate Cancer
BACKGROUND: The role of local radiotherapy in metastatic castration-resistant prostate cancer (mCRPC) remains undefined. This study aimed to identify the value of local radiotherapy and potential candidates for mCRPC. METHODS: A total of 215 patients with mCRPC treated with or without cytoreductive...
Autores principales: | Mai, Lixin, Zhang, Zitong, Li, Yonghong, Liu, Ruiqi, Li, Jibin, Huang, Sijuan, Lin, Maosheng, Liu, Boji, Cao, Wufei, Wu, Jianhua, Liu, Mengzhong, Zhou, Fangjian, Liu, Yang, He, Liru |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7746838/ https://www.ncbi.nlm.nih.gov/pubmed/33344256 http://dx.doi.org/10.3389/fonc.2020.606133 |
Ejemplares similares
-
Cytoreductive radiotherapy combined with abiraterone in metastatic castration-resistance prostate cancer: a single center experience
por: Liu, Yang, et al.
Publicado: (2021) -
Survival Outcomes and Prognostic Analysis Following Greater Cytoreductive Radiotherapy in Patients With Metastatic Prostate Cancer
por: Zhang, Zitong, et al.
Publicado: (2020) -
Successful management of prostate cancer with bulky pelvic lymph node metastases after rapid development of castration-resistant prostate cancer: a case report with review of the literature
por: Mai, Lixin, et al.
Publicado: (2020) -
Survival Outcomes After Adding Stereotactic Body Radiotherapy to Metastatic Renal Cell Carcinoma Patients Treated With Tyrosine Kinase Inhibitors
por: He, Liru, et al.
Publicado: (2020) -
Metastasis-directed stereotactic body radiotherapy for oligometastatic renal cell carcinoma: extent of tumor burden eradicated by radiotherapy
por: Liu, Yang, et al.
Publicado: (2021)